RecruitingNCT06635954

A Prospective Real World Evidence Study (PROWES) for Concordance Rate of Blood-based 3D Genome Conformation Mapping (Episwitch CiRT®) to Identify Likelihood of Response and Actual Response Rates to PD-(L)-1 Checkpoint Inhibitors Across Multiple Oncological Indications.

Sponsor

Oxford Biodynamics Inc.

Enrollment

2,000 participants

Start Date

May 14, 2024

Study Type

OBSERVATIONAL

Conditions

Cancer Immunotherapy PD-1 Immune Checkpoint Therapy PD-L1

Summary

The purpose of this research is to test whether a blood-based 3D genome conformation mapping test called the Episwitch CiRT® can help to identify likelihood of response to PD-(L)-1 checkpoint inhibitors (a class of cancer drugs) across multiple oncological indications by comparing the results to actual treatment responses for cancer patients.

Eligibility

Min Age: 18 Years

Inclusion Criteria7

18 years of age or older
Stage III or IV cancer
Selected by their healthcare provider to receive the Episwitch CiRT® test according to the current evidence-based schedule (per protocol) as part of their standard of practice.
ECOG performance status ≤ 2
Clinically eligible for ICI therapy
Able to read, understand and provide written informed consent.
Willing and able to comply with the study requirements